Please login to the form below

Not currently logged in
Email:
Password:

Vibativ

This page shows the latest Vibativ news and features for those working in and with pharma, biotech and healthcare.

Cell wall inhibitors for bacterial infections

Cell wall inhibitors for bacterial infections

intravenously administered cephalosporin; and telavancin (Vibativ; Theravance), a once-daily, intravenously administered bactericidal lipoglycopeptide.

Latest news

  • Clinigen reshuffles management to prepare for growth

    acquisition of Cardioxane from Novartis and in-licensing of Vibativ from Theravance.

  • US FDA approves Vibativ for lung infection caused by MRSA US FDA approves Vibativ for lung infection caused by MRSA

    Vibativ offers effectiveness in these difficult to treat infections when alternative therapies are not suitable.". ... The lung infection indication adds to Vibativ's existing FDA approval to treat complicated skin and skin structure infection.

  • Vibativ is granted marketing authorisation

    European marketing authorisation has been granted for Vibativ, a once-daily injection to treat hospital acquired nosocomial pneumonia. ... Vibativ provides an "effective hospital antibiotic option for patients with hospital-acquired pneumonia caused by

  • GSK increases stake in Theravance

    As well as its projects with GSK, Theravence is currently working with Astellas for the global development and commercialization of antibacterial Vibativ (telavancin).

  • GSK increases Theravance investment

    Theravance also has a partnership with Astellas Pharma under which it developed its only marketed product thus far, an injectable antibiotic called Vibativ (telavancin) that was approved last year by the

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group, where our agencies immerse you in the world of the patient...

Latest intelligence

David Atkins
A snapshot of Congenica
PME talks to CEO David Atkins...
Data desires
What are you looking to achieve with data and how are you preparing yourself to react to the results?...
The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...

Infographics